Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine
References (18)
- et al.
Controlled trial of azathioprine in Crohn's disease
Lancet
(1971) - et al.
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
Lancet
(1978) 6-Mercaptopurine and other imunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis
Gastroenterol Clin North Am
(1989)- et al.
Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
Gastroenterology
(1990) - et al.
Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial
Gastroenterology
(1992) - et al.
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease
Gastroenterology
(1995) - et al.
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
Gastroenterology
(1997) - et al.
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
Gastroenterology
(1995) - et al.
Anti-TNF monoclonal antibody therapy produces endoscopic healing in patients with treatment-resistant, active Crohn's disease
Gastroenterology
(1999)
There are more references available in the full text version of this article.
Cited by (221)
Histologic evaluation of disease activity in inflammatory bowel disease
2020, Atlas of Endoscopy Imaging in Inflammatory Bowel DiseaseDoes Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study
2018, Digestive and Liver DiseaseCitation Excerpt :In the first paper, 15 CD patients with post-operative recurrence of ileitis, treated with AZA, reached EH in approximately 40% of cases, after a median time of 18 months [26]. In the 2nd study, 54% of CD patients showed healing of the mucosal lesions located in the ileum and 70% healing of the colonic lesions, after a median time of treatment of 2 years with AZA [27]. More recently, Mantzaris et al., randomized 77 patients with steroid-dependent CD to receive either budesonide or AZA as maintenance treatment for 1 year.
Current trends and challenges in the postoperative medical management of Crohn's disease: A systematic review
2017, American Journal of SurgeryThe Effectiveness and Safety of Methotrexate as the First-Line Immunomodulator of Maintenance Therapy in Pediatric Crohn Disease
2023, Journal of Pediatric Gastroenterology and NutritionMercaptopurine therapy
2023, Pediatric Inflammatory Bowel Disease
Copyright © 1999 Published by Mosby, Inc.